**Background**
Cardiac arrhythmias and myocardial dysfunction following resuscitation are critical clinical challenges that require rapid and precise pharmacological intervention to improve patient survival and organ function. Simultaneously, diabetic complications, such as foot ulcers, are characterized by impaired wound healing due to the accumulation of advanced glycation end products (AGEs) and reduced fibroblast migration. Addressing these diverse pathological states requires agents that can modulate adrenergic receptors or inhibit metabolic enzymes like aldose reductase. In this context, we will introduce an ultra-short-acting cardioselective β1-adrenergic blocker – Esmolol.
**Definition**
Esmolol hydrochloride is a cardioselective β1-adrenergic blocker that also acts as an inhibitor of aldose reductase with an estimated IC50 of 150 µM.
**In Vitro and In Vivo Studies**
The Esmolol description highlights its versatility in treating both cardiovascular and metabolic disorders. Esmolol in vitro studies demonstrate that concentrations of 0-1 mM inhibit aldose reductase activity and reduce sorbitol formation in red blood cells by 59%. Furthermore, treatment with 0.5-1 mM for 10 minutes inhibits the formation of AGEs. In HFF-1, Ea.hy926, and HaCaT cells, Esmolol (0.01-1000 μM; 8-48 h) promotes cell migration without cytotoxicity, although migration is low at 100 and 500 µM.
Regarding Esmolol In Vivo activity, topical application (7%-20%, twice daily) in Streptozotocin-induced diabetic hairless rats improves NO induction, collagen turnover, and hydroxyproline levels, thereby enhancing wound healing. In a permanent coronary artery occlusion (CAO) rat model, a single i.v. dose of 10 mg/kg reduces ventricular ectopic beats by 66% and significantly decreases the incidence and duration of ventricular tachycardia (VT) and ventricular fibrillation (VF) by upregulating the NK1 receptor. Additionally, in inbred wuzhishan miniature pigs, the administration of 300 μg/kg Esmolol combined with 20 μg/kg Epinephrine (i.v., once) protects myocardial tissue and improves post-resuscitation dysfunction by reducing caspase-3 activation and increasing Bcl-2/Bax protein levels. For researchers requiring specific Esmolol technical information or purity standards, these results underscore its potential in multi-systemic research. In conclusion, Esmolol is a potent β1-adrenergic blocker and aldose reductase inhibitor suitable for studying arrhythmias and diabetic wound healing.
Keywords
Esmolol, 81161-17-3, Adrenergic Receptor, Caspase, Apoptosis, Aldose Reductase, Neurokinin Receptor, Beta Receptor, NK receptor, Tachykinin receptor, Blocker, Arrhythmias, Diabetic foot ulcers, fibroblasts, Inhibitor
References
[1] Kulkarni SA, et al. Novel topical esmolol hydrochloride improves wound healing in diabetes by inhibiting aldose reductase, generation of advanced glycation end products, and facilitating the migration of fibroblasts. Front Endocrinol (Lausanne). 2022 Aug 23;13:926129.
[2] Wang LL, et al. Esmolol activates endogenous neurokinin activity inhibiting infarction-induced arrhythmias in rats: novel mechanisms of anti-arrhythmia. Regul Pept. 2013 Sep 10;186:116-22.
[3] Zhang Q, et al. Combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest. PLoS One. 2013 Dec 18;8(12):e82677.